INDUSTRY OVERVIEW
The Psoriatic Arthritis Treatment is Growing at 12.10% and is expected to reach USD24.3Billion by 2033. Below mentioned are some of the dynamics shaping the Psoriatic Arthritis Treatment.Psoriatic Arthritis Treatment Market Size in (USD Billion) CAGR Growth Rate 12.10%
| Study Period | 2020-2033 |
| Market Size (2025): | USD9.8Billion |
| Market Size (2033): | USD24.3Billion |
| CAGR (2025 - 2033): | 12.10% |
| Fastest Growing Region | Latin America |
| Dominating Region | North America |
www.htfmarketinsights.com
Psoriatic arthritis (PsA) is a chronic autoimmune disease that causes joint inflammation and skin lesions. Treatments aim to reduce pain, prevent joint damage, and improve quality of life. Current therapies include NSAIDs, DMARDs, biologics, and corticosteroids, with biologics being the most effective for severe cases. The market is growing due to increased diagnosis, patient awareness, and therapeutic innovation. Biologic injections and oral immunomodulators are central, while biosimilars and personalized medicine offer future opportunities.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Regulatory Landscape
- EMA and FDA pushing for long-term safety data in immunomodulators and biosimilar interchangeability.
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Rising Prevalence Of Autoimmune Diseases, Improved Diagnosis Rates, Aging Population, Access To Biologics, Focus On Quality Of Life Outcomes
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- High Cost Of Biologics, Side Effects And Safety Issues, Long Approval Timelines, Poor Adherence Rates, Disparity In Access Across Regions
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Launch of biosimilars, targeted biologic therapies (e.g., IL-17, TNF inhibitors), digital patient monitoring, combination therapies, telemedicine consultation models
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Development Of Oral Small Molecules, Regional Licensing Deals, Expansion Of Telehealth For Chronic Disease Care, Lifestyle Integration Programs, New Mechanism-based Drug Targets
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- NSAIDs
- DMARDs
- Biologics
- Corticosteroids
Psoriatic Arthritis Treatment Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Hospital treatment
- Rheumatology clinics
- Telehealth
- Self-injection
- Pharmacy-based care
Psoriatic Arthritis Treatment Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Latin America is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Latin America
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- AbbVie (USA)
- Amgen (USA)
- Johnson & Johnson (USA)
- Novartis (Switzerland)
- Eli Lilly (USA)
- Pfizer (USA)
- UCB Pharma (Belgium)
- Bristol Myers Squibb (USA)
- Sun Pharma (India)
- Biogen (USA)
- Boehringer Ingelheim (Germany)
- Merck & Co. (USA)
- Glenmark (India)
- Galapagos NV (Belgium)
Psoriatic Arthritis Treatment Market Segmentation by Players
www.htfmarketinsights.com
Regional Analysis
- High prevalence in Western nations; uptake of advanced therapies faster in U.S. and EU5 markets.
Market Entropy
- July 2025 – Johnson & Johnson submitted an sBLA to the FDA to update TREMFYA®’s label with Phase 3b APEX data showing joint damage inhibition. July 2025 – BMS’s sNDA for Sotyktu® was accepted by the FDA for PsA. September 2024 – FDA approved Bimzelx® for psoriatic arthritis.
Merger & Acquisition
- April 2024 – ARCA Biopharma and Oruka Therapeutics agreed to merge in an all‑stock deal aimed at advancing Oruka’s pipeline of novel biologics for plaque psoriasis and psoriatic arthritis treatment.
Regulatory Landscape
- EMA and FDA pushing for long-term safety data in immunomodulators and biosimilar interchangeability.
Patent Analysis
- Patents cluster around IL inhibitors, oral small molecules, and dual-action biologics.
Investment and Funding Scenario
- Strong growth driven by rising awareness, earlier diagnosis, and DTC campaigns.
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2025 |
|
Based Year Market Size (2023) |
USD9.8Billion |
|
Historical Period |
2020 to 2025 |
|
CAGR (2025 to 2033) |
12.10% |
|
Forecast Period |
2025 to 2033 |
|
Forecasted Period Market Size (2033) |
USD24.3Billion |
|
Scope of the Report |
Segmentation by Type NSAIDs,DMARDs,Biologics,Corticosteroids, Segmentation by Application Hospital treatment,Rheumatology clinics,Telehealth,Self-injection,Pharmacy-based care, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
AbbVie (USA),Amgen (USA),Johnson & Johnson (USA),Novartis (Switzerland),Eli Lilly (USA),Pfizer (USA),UCB Pharma (Belgium),Bristol Myers Squibb (USA),Sun Pharma (India),Biogen (USA),Boehringer Ingelheim (Germany),Merck & Co. (USA),Glenmark (India),Galapagos NV (Belgium) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Psoriatic Arthritis Treatment - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Psoriatic Arthritis Treatment Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Psoriatic Arthritis Treatment Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Psoriatic Arthritis Treatment Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising prevalence of autoimmune diseases, improved diagnosis rates, aging population, access to biologics, focus on quality of life outcomes
-
3.2 Available Opportunities
- 3.2.1 Development of oral small molecules, regional licensing deals, expansion of telehealth for chronic disease care, lifestyle integration programs, new mechanism-based drug targets
-
3.3 Influencing Trends
- 3.3.1 Launch of biosimilars, targeted biologic therapies (e.g., IL-17, TNF inhibitors), digital patient monitoring, combination therapies, telemedicine consultation models
-
3.4 Challenges
- 3.4.1 High cost of biologics, side effects and safety issues, long approval timelines, poor adherence rates, disparity in access across regions
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Psoriatic Arthritis Treatment Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Psoriatic Arthritis Treatment Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Psoriatic Arthritis Treatment : Competition Benchmarking & Performance Evaluation
- 5.1 Global Psoriatic Arthritis Treatment Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Psoriatic Arthritis Treatment Revenue 2025
- 5.3 Global Psoriatic Arthritis Treatment Sales Volume by Manufacturers (2025)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Strategic Group Analysis
- 5.6 5C’s Analysis
Chapter 6: Global Psoriatic Arthritis Treatment Market: Company Profiles
- 6.1 AbbVie (USA)
- 6.1.1 AbbVie (USA) Company Overview
- 6.1.2 AbbVie (USA) Product/Service Portfolio & Specifications
- 6.1.3 AbbVie (USA) Key Financial Metrics
- 6.1.4 AbbVie (USA) SWOT Analysis
- 6.1.5 AbbVie (USA) Development Activities
- 6.2 Amgen (USA)
- 6.3 Johnson & Johnson (USA)
- 6.4 Novartis (Switzerland)
- 6.5 Eli Lilly (USA)
- 6.6 Pfizer (USA)
- 6.7 UCB Pharma (Belgium)
- 6.8 Bristol Myers Squibb (USA)
- 6.9 Sun Pharma (India)
- 6.10 Biogen (USA)
- 6.11 Boehringer Ingelheim (Germany)
- 6.12 Merck & Co. (USA)
- 6.13 Glenmark (India)
- 6.14 Galapagos NV (Belgium)
- 6.15 Almirall (Spain)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Psoriatic Arthritis Treatment by Type & Application (2020-2033)
-
7.1 Global Psoriatic Arthritis Treatment Market Revenue Analysis (USD Million) by Type (2020-2025)
- 7.1.1 NSAIDs
- 7.1.2 DMARDs
- 7.1.3 Biologics
- 7.1.4 Corticosteroids
- 7.1.5 TNF Inhibitors
-
7.2 Global Psoriatic Arthritis Treatment Market Revenue Analysis (USD Million) by Application (2020-2025)
- 7.2.1 Hospital Treatment
- 7.2.2 Rheumatology Clinics
- 7.2.3 Telehealth
- 7.2.4 Self-injection
- 7.2.5 Pharmacy-based Care
- 7.3 Global Psoriatic Arthritis Treatment Market Revenue Analysis (USD Million) by Type (2025-2033)
- 7.4 Global Psoriatic Arthritis Treatment Market Revenue Analysis (USD Million) by Application (2025-2033)
Chapter 8 : North America Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 8.1 North America Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 8.2.1 NSAIDs
- 8.2.2 DMARDs
- 8.2.3 Biologics
- 8.2.4 Corticosteroids
- 8.2.5 TNF Inhibitors
-
8.3 North America Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 8.3.1 Hospital Treatment
- 8.3.2 Rheumatology Clinics
- 8.3.3 Telehealth
- 8.3.4 Self-injection
- 8.3.5 Pharmacy-based Care
- 8.4 North America Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 8.5 North America Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 8.6 North America Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 9.1 LATAM Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 9.2.1 NSAIDs
- 9.2.2 DMARDs
- 9.2.3 Biologics
- 9.2.4 Corticosteroids
- 9.2.5 TNF Inhibitors
-
9.3 LATAM Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 9.3.1 Hospital Treatment
- 9.3.2 Rheumatology Clinics
- 9.3.3 Telehealth
- 9.3.4 Self-injection
- 9.3.5 Pharmacy-based Care
- 9.4 LATAM Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 9.5 LATAM Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 9.6 LATAM Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 10 : West Europe Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 10.1 West Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 10.2.1 NSAIDs
- 10.2.2 DMARDs
- 10.2.3 Biologics
- 10.2.4 Corticosteroids
- 10.2.5 TNF Inhibitors
-
10.3 West Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 10.3.1 Hospital Treatment
- 10.3.2 Rheumatology Clinics
- 10.3.3 Telehealth
- 10.3.4 Self-injection
- 10.3.5 Pharmacy-based Care
- 10.4 West Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 10.5 West Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 10.6 West Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 11 : Central & Eastern Europe Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 11.2.1 NSAIDs
- 11.2.2 DMARDs
- 11.2.3 Biologics
- 11.2.4 Corticosteroids
- 11.2.5 TNF Inhibitors
-
11.3 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 11.3.1 Hospital Treatment
- 11.3.2 Rheumatology Clinics
- 11.3.3 Telehealth
- 11.3.4 Self-injection
- 11.3.5 Pharmacy-based Care
- 11.4 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 11.5 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 11.6 Central & Eastern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 12 : Northern Europe Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 12.2.1 NSAIDs
- 12.2.2 DMARDs
- 12.2.3 Biologics
- 12.2.4 Corticosteroids
- 12.2.5 TNF Inhibitors
-
12.3 Northern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 12.3.1 Hospital Treatment
- 12.3.2 Rheumatology Clinics
- 12.3.3 Telehealth
- 12.3.4 Self-injection
- 12.3.5 Pharmacy-based Care
- 12.4 Northern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 12.5 Northern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 12.6 Northern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 13 : Southern Europe Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 13.2.1 NSAIDs
- 13.2.2 DMARDs
- 13.2.3 Biologics
- 13.2.4 Corticosteroids
- 13.2.5 TNF Inhibitors
-
13.3 Southern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 13.3.1 Hospital Treatment
- 13.3.2 Rheumatology Clinics
- 13.3.3 Telehealth
- 13.3.4 Self-injection
- 13.3.5 Pharmacy-based Care
- 13.4 Southern Europe Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 13.5 Southern Europe Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 13.6 Southern Europe Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 14 : East Asia Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 14.1 East Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 14.2.1 NSAIDs
- 14.2.2 DMARDs
- 14.2.3 Biologics
- 14.2.4 Corticosteroids
- 14.2.5 TNF Inhibitors
-
14.3 East Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 14.3.1 Hospital Treatment
- 14.3.2 Rheumatology Clinics
- 14.3.3 Telehealth
- 14.3.4 Self-injection
- 14.3.5 Pharmacy-based Care
- 14.4 East Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 14.5 East Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 14.6 East Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 15 : Southeast Asia Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 15.2.1 NSAIDs
- 15.2.2 DMARDs
- 15.2.3 Biologics
- 15.2.4 Corticosteroids
- 15.2.5 TNF Inhibitors
-
15.3 Southeast Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 15.3.1 Hospital Treatment
- 15.3.2 Rheumatology Clinics
- 15.3.3 Telehealth
- 15.3.4 Self-injection
- 15.3.5 Pharmacy-based Care
- 15.4 Southeast Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 15.5 Southeast Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 15.6 Southeast Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 16 : South Asia Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 16.1 South Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 16.2.1 NSAIDs
- 16.2.2 DMARDs
- 16.2.3 Biologics
- 16.2.4 Corticosteroids
- 16.2.5 TNF Inhibitors
-
16.3 South Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 16.3.1 Hospital Treatment
- 16.3.2 Rheumatology Clinics
- 16.3.3 Telehealth
- 16.3.4 Self-injection
- 16.3.5 Pharmacy-based Care
- 16.4 South Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 16.5 South Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 16.6 South Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 17 : Central Asia Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 17.1 Central Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 17.2.1 NSAIDs
- 17.2.2 DMARDs
- 17.2.3 Biologics
- 17.2.4 Corticosteroids
- 17.2.5 TNF Inhibitors
-
17.3 Central Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 17.3.1 Hospital Treatment
- 17.3.2 Rheumatology Clinics
- 17.3.3 Telehealth
- 17.3.4 Self-injection
- 17.3.5 Pharmacy-based Care
- 17.4 Central Asia Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 17.5 Central Asia Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 17.6 Central Asia Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 18 : Oceania Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 18.1 Oceania Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 18.2.1 NSAIDs
- 18.2.2 DMARDs
- 18.2.3 Biologics
- 18.2.4 Corticosteroids
- 18.2.5 TNF Inhibitors
-
18.3 Oceania Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 18.3.1 Hospital Treatment
- 18.3.2 Rheumatology Clinics
- 18.3.3 Telehealth
- 18.3.4 Self-injection
- 18.3.5 Pharmacy-based Care
- 18.4 Oceania Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 18.5 Oceania Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 18.6 Oceania Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 19 : MEA Psoriatic Arthritis Treatment Market Breakdown by Country, Type & Application
- 19.1 MEA Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2020-2025]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2020-2025]
- 19.2.1 NSAIDs
- 19.2.2 DMARDs
- 19.2.3 Biologics
- 19.2.4 Corticosteroids
- 19.2.5 TNF Inhibitors
-
19.3 MEA Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2020-2025]
- 19.3.1 Hospital Treatment
- 19.3.2 Rheumatology Clinics
- 19.3.3 Telehealth
- 19.3.4 Self-injection
- 19.3.5 Pharmacy-based Care
- 19.4 MEA Psoriatic Arthritis Treatment Market by Country (USD Million) & Sales Volume (Units) [2026-2033]
- 19.5 MEA Psoriatic Arthritis Treatment Market by Type (USD Million) & Sales Volume (Units) [2026-2033]
- 19.6 MEA Psoriatic Arthritis Treatment Market by Application (USD Million) & Sales Volume (Units) [2026-2033]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Psoriatic Arthritis Treatment market may reach an estimated size of USD 24.3 Billion by 2033.
The Psoriatic Arthritis Treatment Market is predicted to grow at a CAGR of 12.10%.
Some of the prominent trends that are influencing and driving the growth of Global Psoriatic Arthritis Treatment Market are Launch Of Biosimilars, Targeted Biologic Therapies (e.g., IL-17, TNF Inhibitors), Digital Patient Monitoring, Combination Therapies, Telemedicine Consultation Models
- Rising Prevalence Of Autoimmune Diseases, Improved Diagnosis Rates, Aging Population, Access To Biologics, Focus On Quality Of Life Outcomes
As Industry players prepare to scale up, Psoriatic Arthritis Treatment Market sees major concern such as High Cost Of Biologics, Side Effects And Safety Issues, Long Approval Timelines, Poor Adherence Rates, Disparity In Access Across Regions.
Some of the opportunities that Analyst at HTF MI have identified in Psoriatic Arthritis Treatment Market are:
- Development Of Oral Small Molecules, Regional Licensing Deals, Expansion Of Telehealth For Chronic Disease Care, Lifestyle Integration Programs, New Mechanism-based Drug Targets
Psoriatic Arthritis Treatment Market identifies market share by players along with the concentration rate using CR4, CR8 Index to determine leading and emerging competitive players such as AbbVie (USA),Amgen (USA),Johnson & Johnson (USA),Novartis (Switzerland),Eli Lilly (USA),Pfizer (USA),UCB Pharma (Belgium),Bristol Myers Squibb (USA),Sun Pharma (India),Biogen (USA),Boehringer Ingelheim (Germany),Merck & Co. (USA),Glenmark (India),Galapagos NV (Belgium),Almirall (Spain).
The Global Psoriatic Arthritis Treatment Market Study is Broken down by applications such as Hospital treatment,Rheumatology clinics,Telehealth,Self-injection,Pharmacy-based care.
The Global Psoriatic Arthritis Treatment Market Study is segmented by NSAIDs,DMARDs,Biologics,Corticosteroids,TNF Inhibitors.
The Global Psoriatic Arthritis Treatment Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - Base year: 2025. Forecast period**: 2025 to 2033 [** unless otherwise stated]
Psoriatic arthritis (PsA) is a chronic autoimmune disease that causes joint inflammation and skin lesions. Treatments aim to reduce pain, prevent joint damage, and improve quality of life. Current therapies include NSAIDs, DMARDs, biologics, and corticosteroids, with biologics being the most effective for severe cases. The market is growing due to increased diagnosis, patient awareness, and therapeutic innovation. Biologic injections and oral immunomodulators are central, while biosimilars and personalized medicine offer future opportunities.
